Born : 12 May 1932 (age 89) in New York City, U.S. ([HK00B7][GDrive])
[Dr. Hilary Koprowski (born 1916)] ( "[Dr. Hilary Koprowski (born 1916)] (along with [Dr. Stanley Alan Plotkin (born 1932)] and Tadeusz Wiktor) did significant work on an improved vaccine against rabies.[11] He developed the HDCV rabies vaccine in the 1960s at the Wistar Institute. It was licensed for use in the United States in 1980." ... [HK006N][GDrive] )
Dr. Paul Allan Offit (born 1951) ( "Another vaccine that Plotkin co-developed, working with H. Fred Clark and [Dr. Paul Allan Offit (born 1951)], is for rotavirus. In 2006, the team's vaccine became part of the U.S. recommended vaccine schedule for babies.") - [HK00B7][GDrive]
Vijay B. Samant (born 1952) A top supporter of Plotkin ... [HK00B7][GDrive]
... ( ... )
The Coalition for Epidemic Preparedness Innovations (CEPI) ...
Vical Incorporated ... Plotkin was never employed by Vical, but his work was used by Vical (CMV virus - see https://www.biospace.com/article/releases/vical-incorporated-expands-portfolio-of-cmv-vaccine-technologies-through-license-agreement-with-the-b-wistar-institute-b-/?s=65 ) and he was vocally supported/praised by "Vijay B. Samant, President and CEO of Vical, Inc.[5]"
Alma mater : SUNY Downstate Medical Center
Known for : Vaccinology, immunology
Spouse(s) : Susan Plotkin
Children : 2
Stanley Alan Plotkin (born May 12, 1932[1]) is an American physician who works as a consultant to vaccine manufacturers, such as Sanofi Pasteur, as well as biotechnology firms, non-profits and governments. In the 1960s, he played a pivotal role in discovery of a vaccineagainst rubella virus while working at Wistar Institute in Philadelphia. Plotkin was a member of Wistar’s active research faculty from 1960 to 1991. Today, in addition to his emeritusappointment at Wistar, he is emeritus professor of Pediatrics at the University of Pennsylvania. His book, Vaccines,[2][3] is the standard reference on the subject.[4][5] He is an editor with Clinical and Vaccine Immunology, which is published by the American Society for Microbiologyin Washington, D.C.
Plotkin was born and raised in New York City, the son of Jewish parents, Lee and Joseph Plotkin, who emigrated from England. He attended The Bronx High School of Science in New York City. While attending Bronx Science, at the age of 15, he read a pair of books that greatly influenced his future education and career choices: Arrowsmith by Sinclair Lewis and Microbe Hunters by Paul de Kruif. Deciding to dedicate his life to being a physician and research scientist, Plotkin graduated from Bronx Science in 1948. He then earned his bachelor's degree from New York University in 1952 and went on to earn his MD at SUNY Downstate Medical Center in 1956.[5][6] Plotkin received his GME from the School of Medicine, University of Pennsylvania in 1963.[7][8]
The Wistar Institute of Anatomy and Biology
During his time at Wistar, Plotkin worked on several vaccines; chief among them are vaccines for rubella, rabies, rotavirus, and cytomegalovirus (CMV). He developed a vaccine for rubella, based upon the RA 27/3 strain of the virus (also developed by Plotkin using WI-38, a fetal-derived human cell line), which was released to the public in 1969.[9] This vaccine led to the eradication of the disease in the United States, according to the Centers for Disease Control and Prevention, in 2005.[10] Plotkin, working with Tadeusz Wiktor and [Dr. Hilary Koprowski (born 1916)], produced a human vaccine for rabies during the 1960s and 1970s. This vaccine can be used as a preventive measure for people who have an increased risk of contracting rabies, as well as a treatment for those who have been exposed recently to the disease, preventing infection in nearly 100 percent of cases.[10] Another vaccine that Plotkin co-developed, working with H. Fred Clark and [Dr. Paul Allan Offit (born 1951)], is for rotavirus. In 2006, the team's vaccine became part of the U.S. recommended vaccine schedule for babies.[10] In the 1970s, Plotkin led the development of an experimental vaccine against CMV. This vaccine, developed using attenuated CMV, has yet to make it into commercial production.[10]
"Dr. Plotkin has been a tireless advocate for the protection of humans, and children in particular, from preventable infectious diseases. His lifetime of work on vaccines has led to profound reductions in both morbidity and mortality not only in the United States, but throughout the world. His unbending adherence to the principle of being guided by outstanding science has led him to be admired by his peers. He demonstrates the combination of scholar, scientist and public servant exemplified by Dr. Maxwell Finland." — [Vijay B. Samant (born 1952)], President and CEO of Vical, Inc.[5]
Other positions held
1956: Internship, Cleveland Metropolitan General Hospital[6][5]
1957: Officer, Epidemic Intelligence Service, United States Public Health Service[5]
1959–1973: Instructor, then Associate Professor, School of Medicine, University of Pennsylvania
1961: Resident, Children's Hospital of Philadelphia[4][5]
1962–1963: Resident, Hospital for Sick Children London[4][5]
1964: Joseph P. Kennedy Jr. Foundation scholar[11]
1965–1972: Associate physician, Children's Hospital of Philadelphia
1972–1990: Director of Infectious Diseases and Senior Physician, Children's Hospital of Philadelphia[6][12]
1974–1991: Professor of Pediatrics and Microbiology, School of Medicine, University of Pennsylvania[12]
1984–1986: President, Medical Staff, Children's Hospital of Philadelphia
1991–1998: Medical and Scientific Director Pasteur Merieux Connaught, Marnes-la-Coquette[12]
2003: Professor Emeritus, Wistar Institute
2006: Professor Emeritus of Virology, University of Pennsylvania
2006: Executive Advisor, Sanofi Pasteur
2014: Senior Advisor, Global Virus Network[13]
Associate Chairman, Department of Pediatrics, University of Pennsylvania
Adjunct professor, Johns Hopkins Bloomberg School of Public Health[15]
Scientific advisor, Mymetics[16]
2017 Scientific advisor (and co-founder) of the Coalition for Epidemic Preparedness Innovations (CEPI)[17][18]
1987: James D. Bruce Memorial Award, American College of Physicians[19]
1993: Distinguished Physician Award, Pediatric Infectious Disease Society[20]
1995: Ed Nowakowski Senior Memorial Clinical Virology Award, Pan American Society for Clinical Virology[21]
1998: Chevalier of the French Legion of Honor Medal[22]
2005: Election to the Institute of Medicine of the National Academies[24]
2007: Distinguished Graduate Award, Perelman School of Medicine at the University of Pennsylvania[8]
2009: Maxwell Finland Award for Scientific Achievement[25]
2013: Caspar Wistar Medal of Achievement[26]
2014: Dr. Charles Mérieux Award for Achievement in Vaccinology and Immunology[28]
Plotkin and his wife, Susan, have two children, Michael and Alec. In 1957, Plotkin wanted to join the US Air Force so that he could learn to fly, but instead he went to work for the Epidemic Intelligence Service. He eventually realized his dream of learning to fly at the age of 74.[6]
Scholia has a profile for Stanley Plotkin (Q7599873).
Plotkin, Stanley; Orenstein, Walter; Offit, Paul (2012). Vaccines (sixth ed.). Saunders. ISBN 9781455700905.
Saved as PDF : [HC006U][GDrive]
Mentioned : Dr. Stanley Alan Plotkin (born 1932) / Dr. Jong Joseph Kim (born 1969) / Dr. David B. Weiner (born 1955) / Robert Samuel Langer Jr. (born 1948) / Inovio Pharmaceuticals, Incorporated /
SAN DIEGO--(BUSINESS WIRE)--Jun. 24, 2009-- [Inovio Pharmaceuticals, Incorporated - known at this time as "Inovio Biomedical Corporation" ] (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that [Dr. Stanley Alan Plotkin (born 1932)] has agreed to join the company’s scientific advisory board.
[Dr. Stanley Alan Plotkin (born 1932)] developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. He is Emeritus Professor, Wistar Institute and the University of Pennsylvania, and Executive Advisor to the CEO of Sanofi Pasteur.
Over the course of his career [Dr. Stanley Alan Plotkin (born 1932)] has served as senior assistant surgeon with the Epidemic Intelligence Service, U.S. Public Health Service; director of the Division of Infectious Diseases at Children’s Hospital ofPhiladelphia; associate chairman of the Department of Pediatrics, University of Pennsylvania; and medical and scientific director of Aventis Pasteur.
Dr. Plotkin’s professional awards include the Sabin Foundation Medal (2002); the French Legion Medal of Honor (1998); the Clinical Virology Award, Pan American Group for Rapid Viral Diagnosis (1995); the Distinguished Physician Award, Pediatric Infectious Disease Society (1993); and the Bruce Medal of the American College of Physicians (1987).
[Dr. Jong Joseph Kim (born 1969)] , Inovio’s CEO, stated, “[Dr. Stanley Alan Plotkin (born 1932)] is an internationally renowned virologist who has made significant contributions to the goal of conquering diseases with vaccines. We are honored to have Dr Plotkin join our distinguished panel of scientific advisors, who are committed to helping guide Inovio’s development of DNA vaccines, a potentially vital new generation of vaccines targeting cancers and chronic infectious diseases.”
[Dr. Stanley Alan Plotkin (born 1932)] joins [Dr. David B. Weiner (born 1955)] and [Robert Samuel Langer Jr. (born 1948)] on Inovio's Scientific Advisory Board. Dr. Weiner is Chairman of the Scientific Advisory Board and is a professor of the Department of Pathology & Laboratory Medicine, University of Pennsylvania. Dr. Weiner is considered to be a pioneer of the field of DNA vaccines. Dr. Langer, Germeshausen Professor of Chemical and Biomedical Engineering at theMassachusetts Institute of Technology, is a renowned scientist with numerous distinguished awards. Drs. Weiner and Langer have both advised organizations such as the FDA and multiple life sciences companies. Both Drs. Weiner and Langer have served as founding members of the scientific advisory board of VGX Pharmaceuticals, which merged with Inovio Biomedical on June 1, 2009.